Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOSE Study: Nasal Sprays for HHT Epistaxis
NCT01408030Phase 2Completed
- Start
- Aug 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab, estriol and tranexamic acid in hereditary hemorrhagic telangiectasia (HHT) (4 arms). Primary endpoint: Frequency of Epistaxis. Started Aug 2011; status: completed.
02
Drugs
bevacizumabestrioltranexamic acid
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT01408030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408030.